Publications by authors named "Michael D Jain"

Claim this Profile
E
Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>.
Melissa R Hines, Tristan E Knight, Kevin O McNerney, Mark B Leick, Tania Jain, Michael D Jain

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFNγ-driven skewing towards Th1 over Th17 differentiationunderlies CRSand neutropenia in CAR-T therapy.
Payal Goala, Yongliang Zhang, Nolan J Beatty, Allan Pavy, Shannon L McSain, Michael D Jain

J Clin Invest· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies.
Benjamin Diamond, Dhanvantri Chahar, Michael D Jain, Alexandra M Poos, Michael A Durante

Blood Cancer Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune dysfunction after cancer remission: scar or disease?
Michael D Jain, Jonathan Cools-Lartigue

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma.
Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop, Michael D Jain, Tania Jain

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma.
Michael Winkelmann, Sandeep S Raj, Michael D Jain, Gloria Iacoboni, Fabian Müller

Blood Cancer J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel.
Satabdi Saha, Lubna Rehman, Abdur Rehman, Faezeh Darbaniyan, Donna M Weber, Michael D Jain

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study.
Nikhil Yegya-Raman, John P Plastaras, Christopher M Wright, Monica Chelius, Siqi Zhang, Michael D Jain

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma.
Khushali Jhaveri, Ram Thapa, Dalia Ercan, Aditi Saha, Jerald Noble, Michael D Jain

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma.
Roni Shouval, Christopher Strouse, Soyoung Kim, Temitope Oloyede, Sairah Ahmed, Michael D Jain, Tania Jain

Transplant Cell Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noncanonical and mortality-defining toxicities of CAR T cell therapy.
Kai Rejeski, Joshua A Hill, Saurabh Dahiya, Michael D Jain

Nat Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing.
Xiaoqing Yu, Michael D Jain, Meghan A Menges, Ling Cen, Jerald D Noble

J Immunother Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.
Laura Samples, Hossein Sadrzadeh, Matthew J Frigault, Caron A Jacobson, Mehdi Hamadani, Michael D Jain

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies.
Michael D Jain, Jeremy S Abramson, Stephen M Ansell

Am Soc Clin Oncol Educ Book· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.
Mohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, Patrick Johnston, Madiha Iqbal, Michael D Jain

Bone Marrow Transplant· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged Neurologic Symptoms After CAR T Cell Therapy - What Is It?
Michael D Jain

Transplant Cell Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.
Sepideh Mokhtari, Justin M Asquith, Syeda Saba Kareem, Christina A Bachmeier, Yolanda Pina, Michael D Jain

Int J Mol Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene Ciloleucel.
Aasha I Hoogland, Xiaoyin Li, Karnav Modi, Taylor Welniak, Yvelise Rodriguez, Michael D Jain

Transplant Cell Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RHOA Loss of Function Impairs the IFNγ Response and Promotes CD19 Antigen Escape to Drive CAR-T Resistance in Diffuse Large B-cell Lymphoma.
Austin D Newsam, Bachisio Ziccheddu, Venu Venkatarame Gowda Saralamma, Caroline A Coughlin, Yitzhar E Goretsky, Michael D Jain

bioRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
Rishika Prasad, Abdur Rehman, Lubna Rehman, Faezeh Darbaniyan, Viktoria Blumenberg, Preetesh Jain, Michael D Jain

Blood· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy.
Aasha I Hoogland, Anna Barata, Xiaoyin Li, Nathaly Irizarry-Arroyo, Michael D Jain

Transplant Cell Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies.
Benjamin Diamond, Dhanvantri Chahar, Michael D Jain, Alexandra M Poos, Michael Durante

bioRxiv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John Tamaresis, Armin Ghobadi

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation.
Guy Handley, Amanda Yepes, Eva Eliassen, Gabriel Dominguez, Yanina Pasikhova, Michael D Jain

Open Forum Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.
Pierre Sesques, Amy A Kirkwood, Mi Kwon, Kai Rejeski, Michael D Jain

J Hematol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis